Abstract
High linear energy transfer (LET) radiotherapy has an excellent dose distribution and relative biological effectiveness (RBE). As the RBE of particle beams for therapy is important in terms of determining the dose prescription, we have to evaluate an accurate and reliable assessment method. Recently, several particle therapy facilities will open; however, the dose estimation is still not uniform. We have to confirm the quality assurance procedures among several facilities.
Excellent local effect has been already achieved by treatment of monotherapy of carbon ion radiotherapy. The efficacy of carbon ion radiotherapy has been confirmed by taking advantage of the physical and biological properties. In addition, we have to gain the higher survival rate for locally advanced tumor with potentially metastasis. This paper reviews briefly background of carbon ion radiotherapy, biophysical characters, biological characters, and several radiobiological factors. The potential benefit of multimodality treatment will be also discussed to further improve therapeutic outcomes.
Keywords: Radiation biology, high LET, carbon ion radiotherapy, biological quality assurance, multimodality therapy
Current Signal Transduction Therapy
Title: Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach
Volume: 5 Issue: 3
Author(s): Takeo Takahashi, Yukari Yoshida, Koichi Ando, Hidemasa Kawamura, Masahiko Okamoto, Jun-ichi Saitoh, Hitoshi Ishikawa, Takeshi Ebara, Yoshiyuki Suzuki, Tatsuya Ohno and Takashi Nakano
Affiliation:
Keywords: Radiation biology, high LET, carbon ion radiotherapy, biological quality assurance, multimodality therapy
Abstract: High linear energy transfer (LET) radiotherapy has an excellent dose distribution and relative biological effectiveness (RBE). As the RBE of particle beams for therapy is important in terms of determining the dose prescription, we have to evaluate an accurate and reliable assessment method. Recently, several particle therapy facilities will open; however, the dose estimation is still not uniform. We have to confirm the quality assurance procedures among several facilities.
Excellent local effect has been already achieved by treatment of monotherapy of carbon ion radiotherapy. The efficacy of carbon ion radiotherapy has been confirmed by taking advantage of the physical and biological properties. In addition, we have to gain the higher survival rate for locally advanced tumor with potentially metastasis. This paper reviews briefly background of carbon ion radiotherapy, biophysical characters, biological characters, and several radiobiological factors. The potential benefit of multimodality treatment will be also discussed to further improve therapeutic outcomes.
Export Options
About this article
Cite this article as:
Takahashi Takeo, Yoshida Yukari, Ando Koichi, Kawamura Hidemasa, Okamoto Masahiko, Saitoh Jun-ichi, Ishikawa Hitoshi, Ebara Takeshi, Suzuki Yoshiyuki, Ohno Tatsuya and Nakano Takashi, Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach, Current Signal Transduction Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157436210791920238
DOI https://dx.doi.org/10.2174/157436210791920238 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment of GM2 Gangliosidosis in Adult Sandhoff Mice Using an Intravenous
Self-Complementary Hexosaminidase Vector
Current Gene Therapy The Cone Beam O-Arm Imaging System: Radiation Dose, Image Quality, and Clinical Applications
Recent Patents on Medical Imaging Morin Inhibits Ovarian Cancer Growth through the Inhibition of NF-κB Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Dietary Prevention of Cancer: Anticancer and Antiangiogenic Properties of Green Tea Polyphenols
Medicinal Chemistry Reviews - Online (Discontinued) Electromagnetic Energy as a Bridge Between Atomic and Cellular Levels in the Genetics Approach to Cancer Treatment
Current Topics in Medicinal Chemistry A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity
Current Genomics Targeting Anti-Cancer Active Compounds: Affinity-Based Chromatographic Assays
Current Pharmaceutical Design Long Term Recovery of Diaphragmatic Function in a Patient with Unilateral Diaphragmatic Pacemaker
Current Respiratory Medicine Reviews Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Recent Patents on Anti-Cancer Drug Discovery Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases
Anti-Cancer Agents in Medicinal Chemistry Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine Recent Trends of Chalcones Potentialities as Antiproliferative and Antiresistance Agents
Anti-Cancer Agents in Medicinal Chemistry Reactive Oxygen and Nitrogen Species in Carcinogenesis: Implications of Oxidative Stress on the Progression and Development of Several Cancer Types
Mini-Reviews in Medicinal Chemistry Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Molecular Targeted Therapies in the Management of Head and Neck Squamous Cell Carcinoma: Recent Developments and Perspectives
Anti-Cancer Agents in Medicinal Chemistry The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer
Current Cancer Drug Targets Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology Targeted Gene Therapy for Ovarian Cancer
Current Gene Therapy